WFSBP Programme 2015

78 / 112

76
WFSBP 2015
Scientific Programme | Thursday, 18 June 2015
T40: Schizophrenia: Basic / Clinical
S-53 Symposium
11:00–12:30 MC 2 Room
The impact of tobacco and cannabis use on psychosis
liability and illness long term outcome: Epidemiological
evidence across Europe and Australia
Chair: Nikos C. Stefanis, Greece
Co-Chair: David Castle, Australia
S-53-001
Tobacco and cannabis long term impact on physical health
and clinical outcomes in schizophrenia. Is discontinuation
of substance use feasible?
David Castle, Australia
A. Waterreus, V. Morgan, N. Stefanis, A. Sankaranarayanan,
S. Mancuso
S-53-002
Substance use brings forward the onset of non-affective
psychosis: Potential biological mechanisms and clinical
implications
Nikos C. Stefanis, Greece
M. Dragovic, B. D. Power, A. Jablensky, D. Castle, V. Morgan
S-53-003
Cannabis complexities and why they are important
Amir Englund, United Kingdom
T44: Stimulation Methods (ECT, TMS, VNS, DBS)
S-54 Symposium
11:00–12:30 Kokkali Room
Recent research data in electroconvulsive therapy and
how they inform state of the art clinical practice
Chair: Georgios Petrides, USA
Co-Chair: Declan McLoughlin, Ireland
S-54-001
Bitemporal versus high-dose unilateral twice-weekly elec-
troconvulsive therapy for depression (EFFECT-Dep): A prag-
matic, randomised, non-inferiority trial
Declan McLoughlin, Ireland
S-54-002
Antidepressant efficacy of RUL-Ultra brief pulse ECT: Data
from phase I of the PRIDE study
Charles Kellner, USA
M. Husain, R. Knapp, W. V. McCall, G. Petrides, R. Young,
R. Greenberg, S. McClintock, M. Mueller, J. Prudic, R. Weiner,
S. Lisanby
S-54-003
Differential response to ECT between unipolar and bipolar
depression
Pascal Sienaert, Belgium
S-54-004
Ketamine plus electroconvulsive therapy: Synergistic effects
in the treatment of depression?
Styliani Kaliora, USA
G. Petrides
T40: Schizophrenia: Basic/ Clinical
S-55 Symposium
11:00–12:30 Conference Room 1
New insights of clinical, neurobiological and genetic
aspects in mental illness
Chair: Thomas Schulze, Germany
Co-Chair: Ryota Hashimoto, Japan
S-55-001
Current genetic approaches to major psychiatric disorders
Thomas Schulze, Germany
S-55-002
Recent advances in neuroinflammation relevant to schizo­
phrenia therapeutics
Thomas Weickert, Australia
S. Fillman, R. Lenroot, V. Catts, J. Bruggemann, S. Catts,
C. Weickert
S-55-003
New glia world to psychiatry: Brain function and mental
disorders
Manabu Makinodan, Japan
S-55-004
Intermediate phenotype strategy for discovering disease
related gene network
Ryota Hashimoto, Japan
K. Ohi, M. Ikeda, H. Yamamori, Y. Yasuda, M. Fujimoto,
M. Fukunaga, H. Fujino, Y. Watanabe, N. Iwata, M. Takeda
T23: Neuroimaging: Genetic, Functional, Structural
S-56 Symposium
15:00–16:30 Trianti Hall
Development of biomarkers for neuropsychiatric disor-
ders: State-of-the-art and challenges ahead
Chair: Nikolaos Koutsouleris, Germany
Co-Chair: Christos Davatzikos, USA
S-56-002
Machine learning biomarkers for individualized outcome
prediction in functional psychoses
Lena Palaniyappan, United Kingdom
S. Guo, G. Deshpande, P. Liddle